Sun Pharmaceutical Industries Ltd (SUN.BO)
19 Dec 2014
|Market Cap (Mil.):||Rs1,673,190.00|
|Shares Outstanding (Mil.):||2,071.16|
GLOBAL MARKETS ROUNDUP * Asian share markets were mostly in the red on Tuesday while the U.S. dollar began to edge higher once again aided by a media report the Federal Reserve might take a rhetorical step toward tightening at its meeting next week. * The yen held onto sizeable gains early on Tuesday, having staged a broad short-covering rally as a big drop in oil prices hit global risk appetite. Both the dollar and euro fell from multi-year peaks with the greenback sliding to 120.
(Adds Mizuho, Oriola-KD, Sharp, Vattenfall, TriMas Corp, Abris Capital)
(Removes erroneous reference to Canadian Solar in Sharp Corp item)
MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories , but ordered the firms to divest seven products to ensure the deal doesn't harm competition.
MUMBAI - Sun Pharmaceutical Industries, India's largest drugmaker by revenue, on Thursday posted a 15 percent rise in quarterly net profit, roughly in line with expectations, helped by strong growth in sales in the domestic market.
MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd on Tuesday reported its first profit in six quarters after benefiting from the exclusive U.S. launch of a cheaper copy of Novartis AG blood pressure pill Diovan.
* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)
Reuters Market Eye - Ranbaxy Laboratories gains 4.5 percent. Sun Pharmaceutical Industries , which is in the process of acquiring Ranbaxy, also jumps 4.4 percent.
* Ranbaxy Laboratories gains 4.5 percent. * Sun Pharmaceutical Industries, which is in the process of acquiring Ranbaxy, also jumps 4.4 percent. * Ranbaxy posts a profit of 4.78 billion rupees ($78 million), compared with a loss of 4.5 billion rupees a year earlier. * The company's earnings got a boost from the launch of generic Valsartan in the U.S. with 180 days exclusivity - Analysts. * Valsartan is a cheaper copy of Novartis AG's blood pressure pill Diovan. * The Indian pharma index gaine
Reuters Market Eye - Sun Pharmaceutical Industries gains 3.3 percent.